

# Stefania Crucitta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4811861/publications.pdf>

Version: 2024-02-01

51  
papers

1,324  
citations

361413

20  
h-index

361022

35  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2505  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>European Urology</i> , 2017, 71, 680-687.	1.9	213
2	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <i>British Journal of Cancer</i> , 2018, 118, 820-824.	6.4	190
3	Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 57-62.	2.5	71
4	Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment. <i>Stem Cells Translational Medicine</i> , 2018, 7, 305-314.	3.3	65
5	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3951.	4.1	62
6	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. <i>Cancer Treatment Reviews</i> , 2017, 55, 71-82.	7.7	56
7	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. <i>Cancer Treatment Reviews</i> , 2020, 84, 101966.	7.7	44
8	From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. <i>Lung Cancer</i> , 2019, 131, 78-85.	2.0	42
9	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. <i>Oncotarget</i> , 2018, 9, 6630-6643.	1.8	42
10	The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. <i>British Journal of Cancer</i> , 2018, 119, 1252-1258.	6.4	39
11	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 556-563.	2.0	35
12	Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?. <i>Pharmacological Research</i> , 2016, 107, 398-406.	7.1	32
13	Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells. <i>Stem Cells</i> , 2018, 36, 633-640.	3.2	32
14	Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer. <i>BJU International</i> , 2019, 124, 693-700.	2.5	32
15	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	4.2	27
16	Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. <i>Molecular Cancer</i> , 2021, 20, 32.	19.2	27
17	Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 593831.	2.8	25
18	Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. <i>Clinical Lung Cancer</i> , 2020, 21, 232-237.	2.6	24

#	ARTICLE	IF	CITATIONS
19	The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. <i>Pharmacogenomics</i> , 2019, 20, 49-68.	1.3	23
20	PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. <i>Pharmacological Research</i> , 2021, 163, 105241.	7.1	23
21	erbB in NSCLC as a molecular target: current evidences and future directions. <i>ESMO Open</i> , 2020, 5, e000724.	4.5	22
22	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	7.7	21
23	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. <i>Pharmacogenomics</i> , 2018, 19, 727-740.	1.3	20
24	The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. <i>BMC Cancer</i> , 2019, 19, 410.	2.6	16
25	Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12136.	12.2	15
26	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. <i>Pharmacological Research</i> , 2021, 169, 105643.	7.1	13
27	CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats. <i>Journal of Virology</i> , 2021, 95, e0135821.	3.4	13
28	Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. <i>Communications Biology</i> , 2021, 4, 370.	4.4	12
29	Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. <i>Pharmacogenomics Journal</i> , 2021, 21, 233-242.	2.0	11
30	CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 527-533.	2.3	9
31	Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 51-59.	4.4	8
32	Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. <i>Neuro-Oncology</i> , 2019, 21, 1610-1611.	1.2	8
33	Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase. <i>Current Pharmaceutical Design</i> , 2017, 23, 2028-2034.	1.9	7
34	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102812.	4.4	7
35	Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3738.	3.7	7
36	Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1219-1227.	2.3	6

#	ARTICLE	IF	CITATIONS
37	A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study. <i>Cancers</i> , 2021, 13, 5128.	3.7	6
38	<i>Apc</i> driven colon carcinogenesis in pirc rat is strongly reduced by polyethylene glycol. <i>International Journal of Cancer</i> , 2015, 137, 2270-2273.	5.1	4
39	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 757-766.	3.1	4
40	Gene Expression Profile of Colon Mucosa after Cytotoxic Insult in wt and Apc-Mutated Pirc Rats: Possible Relation to Resistance to Apoptosis during Carcinogenesis. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	2
41	Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation. <i>Frontiers in Oncology</i> , 2021, 11, 674604.	2.8	2
42	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 760-774.	1.7	1
43	Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15794-e15794.	1.6	1
44	Correlation of expression of TK1 in plasma-derived exosomes with clinical response to CDK4/6 inhibitors in breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12037-12037.	1.6	1
45	Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management. <i>Pharmacogenomics</i> , 2022, 23, 119-134.	1.3	1
46	Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Élisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>Eur Urol</i> 2017;71:680-7. <i>European Urology</i> , 2018, 73, e11-e12.	1.9	0
47	Circulating biomarkers of response to immunotherapy in cancer treatment. <i>Pharmacogenomics</i> , 2019, 20, 1247-1249.	1.3	0
48	KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20526-e20526.	1.6	0
49	Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 210-210.	1.6	0
50	Selective induction of PD-L1 expression in plasma-derived exosomes by gem-nab-paclitaxel vs. folfirinox in pancreas cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24128-e24128.	1.6	0
51	Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14054-e14054.	1.6	0